WESTLAKE VILLAGE, Calif., July 31, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological di… […]
TORRANCE, Calif, July 31, 2020 (GLOBE NEWSWIRE) — Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, provided today additional operational updates for the year ended December 31, 2019 as well as operational updates … […]
CARSON, Calif.–(BUSINESS WIRE)–Tiger Woods’ TGR Foundation, the United States Tennis Association (USTA), The Walt Disney Company, philanthropist Doug Kimmelman and the Karsh Family Foundation have committed $50 million toward the nation’s largest aca… […]
Larry Edwards
→ As La Jolla Pharmaceutical closed on their acquisition of Tetraphase on Wednesday, the San Diego biotech also announced that they’re taking the president and CEO right along with them as Larry Edwards steps in. Edwards, who had a 15-yea… […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix announces first commercial implant of ALTO Abdominal Stent Graft System & official start of U.S. commercial release […]
Phase III advance trial data for AbbVie’s migraine prevention drug atogepant look good — but are the results good enough to rival Biohaven’s two-in-one treatment and prevention drug, rimegepant, sold as Nurtec?
AbbVie picked up atogepant from Allergan … […]
TORRANCE Calif., July 29, 2020 (GLOBE NEWSWIRE) — Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that the European Medicines Agency (EMA) issued scientific advice to Emmaus regarding the clinical… […]
PASADENA, Calif.–(BUSINESS WIRE)—- $arwr–Amgen pays Arrowhead $20 million milestone for start of Phase 2 study of AMG 890 formerly ARO-LPA […]
MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release second quart… […]
Five years after Amgen $AMGN agreed to wager up to $1.8 billion on an alliance with Xencor that spotlighted their preclinical bispecific T cell engager program directed at CD38 and CD3 for multiple myeloma, the big biotech is walking away from the prog… […]
Copyright © 2021 Biotech Networks, LLC
